Tyra Biosciences: 'Hold' IR-NMIBC Data September 9th 2026, With Caution Ahead For 2027 ReadoutsSeeking Alpha · Sep 6, 2026
Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026PRNewsWire · Sep 4, 2026
Tyra Biosciences: SURF302 Is A Worthwhile Binary BetSeeking Alpha · Aug 10, 2026Surface Oncology, Inc. is a clinical-stage biotechnology firm focused on discovering and developing innovative immuno-oncology treatments for cancer patients in the United States. Its pipeline features a range of antibody-based therapeutics, including NZV930, a fully human IgG4 monoclonal antibody designed to modulate extracellular adenosine production, and SRF617, another human IgG4 monoclonal antibody that aims to block CD39's enzymatic activity, thereby influencing adenosine levels and ATP degradation. Other key candidates include SRF388, which targets interleukin 27; GSK4381562, an antibody aimed at CD112R, an inhibitory protein found on natural killer and T cells; and SRF114, which targets the chemokine receptor CCR8.